Cellular Immunology Laboratory
Department of Zoology, UoB
Publications
For Full List of Publications, Citations
Selected Publications from The University of Burdwan (2020-2024)
Ankush Paladhi, Samrat Daripa, Arghya Nath, Sumit Kumar Hira; TLR7-Induced Mitochondrial Reactive Oxygen Species Production in Monocyte-derived Dendritic Cells Drives IL-12–Dependent NK Cell Activation and Enhances Antitumor Immunity . J Immunol 2024;
Dendritic cell (DC)-based vaccines are promising for cancer immunotherapy, but the role of DC-NK cell interactions is not fully understood. This study identified a novel TLR7/mitochondrial reactive oxygen species (mROS)/IL-12 axis that enhances NK cell responses. TLR7 activation by imiquimod in monocyte-derived DCs triggered mROS production, boosting IL-12 secretion and NK cell activation, resulting in increased IFN-γ production and tumor cytotoxicity. mROS neutralization blocked NK cell–mediated tumor lysis, and TLR7-induced NK cell activation occurred independently of MyD88, involving the noncanonical NF-κB pathway. Targeting this axis could improve the effectiveness of DC-based cancer immunotherapy.
Paladhi A, Daripa S, Mondal I and Hira SK (2022) Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity. Front. Immunol. 13:988071.
T-cell exhaustion drives resistance in microsatellite-stable colorectal cancer (CRC) to immunotherapy. Targeting thymidine phosphorylase (TYMP) with tipiracil hydrochloride induces immunological cell death, transforming tumors into 'hot' ones. Chemoimmunotherapy converts Treg cells, eliminates macrophages, and prevents T-cell exhaustion, supporting TYMP targeting for enhanced anticancer effects
Rej A, Paladhi A, Daripa S, Sarkar D, Bhattacharyya S, Mondal I, Hira SK, Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma, International Immunopharmacology, Volume 114, 2023, 109521,
In aggressive B-cell non-Hodgkin lymphoma (B-NHL), the combination of doxorubicin and TGFβRI inhibitor galunisertib (LY2157299) is evaluated for enhanced anticancer effects without exacerbating adverse effects. Galunisertib sensitizes B-NHL cells to doxorubicin, increasing apoptosis synergistically. The combination inhibits TGF-β/Smad2/3 and PI3K/AKT pathways, reducing tumor growth and improving survival. In vivo, the therapy prevents CD8+ T-cell exhaustion and regulatory T-cell exacerbation, supporting its clinical relevance.
Hira, S. K., Rej, A., Paladhi, A., Singh, R., Saha, J., Mondal, I., Bhattacharyya, S., and Manna, P. P. (2020) Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma. iScience 23, 101623
Galunisertib, a TGF-β receptor-I inhibitor, enhances immunotherapy with IL-15-activated dendritic cells in metastatic lymphoma. The combined treatment reduces regulatory T cells, downregulates p-SMAD2 and Neuropilin-1, improving prognosis.